Pancreatic Cancer Research

ResearcherUniversitat de ValènciaActive in the last 2 years

Andrès M.R. Cervantes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3806-3691; OpenAlex author ID A5091727687. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 11

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples. Co-author DOI 10.1111/cyt.70055↗
  3. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  4. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  6. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast pr… Co-author DOI 10.1016/j.trsl.2024.05.003↗
  7. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Co-author DOI 10.3390/cancers13050994↗
  8. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Last author DOI 10.1136/esmoopen-2020-000929↗
  9. Borderline resectable pancreatic cancer. Challenges and controversies. Last author DOI 10.1016/j.ctrv.2018.06.006↗
  10. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… Co-author DOI 10.1155/2018/2373868↗
  11. mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. Co-author DOI 10.18632/oncotarget.20076↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marisol Huerta · 7 shared papers, 2018–2026 · strength 0.94
  2. Luis Sabater-Orti · 6 shared papers, 2017–2026 · strength 0.74
  3. Clara Alfaro‐Cervelló · 4 shared papers, 2020–2026 · strength 0.60
  4. Andrew L. Coveler · 3 shared papers, 2025–2026 · strength 0.57
  5. Marina Garcés‐Albir · 4 shared papers, 2018–2024 · strength 0.44
  6. Susana Roselló · 4 shared papers, 2018–2024 · strength 0.44
  7. Benedito A. Carneiro · 2 shared papers, 2025–2026 · strength 0.41
  8. Devalingam Mahalingam · 2 shared papers, 2025–2026 · strength 0.41
  9. Vaibhav Sahai · 2 shared papers, 2025–2026 · strength 0.41
  10. Mary F. Mulcahy · 2 shared papers, 2025–2026 · strength 0.41
  11. Noelia Tarazona · 3 shared papers, 2020–2024 · strength 0.37
  12. Dimitri Dorcaratto · 3 shared papers, 2018–2024 · strength 0.32
  13. Raquel Antón‐Peñalver · 1 shared paper, 2026 · strength 0.24
  14. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  15. Noelle K. LoConte · 1 shared paper, 2026 · strength 0.22
  16. Anne Ploquin · 1 shared paper, 2026 · strength 0.22
  17. Petr Kavan · 1 shared paper, 2026 · strength 0.22
  18. Ryan Michael Carr · 1 shared paper, 2026 · strength 0.22
  19. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.22
  20. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  21. Charles D. Lopez · 1 shared paper, 2026 · strength 0.22
  22. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
  23. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
  24. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
  25. Anwaar Saeed · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.